J Tack1, J Pokrotnieks2, G Urbonas3, C Banciu4, V Yakusevich5, I Bunganic6, H Törnblom7, Y Kleban8, P Eavis9, M Tsuchikawa10, T Miyagawa10. 1. Division of Gastroenterology, University Hospital Leuven, TARGID, University of Leuven, Belgium, Leuven. 2. Pauls Stradins Clinical University Hospital, Riga Stradiņš University, Riga, Latvia. 3. Department of Family Medicine, Lithuanian University of Health Sciences, Kaunas, Lithuania. 4. Department of Internal Medicine, University of Medicine and Pharmacy Timisoara, Timisoara, Romania. 5. Clinical Hospital named after N.V. Solovyov, Yaroslavl, Russia. 6. Department of Gastroenterology, IBD Centrum of Biologic Therapy, Presov, Slovakia. 7. Department of Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. 8. Railway Clinical Hospital No. 2 of Station Kyiv of South-West Railway, Kyiv, Ukraine. 9. Oldfield Surgery, Bath, UK. 10. Zeria Shinyaku Kogyo Kabushiki Kaisha, Chuo-ku, Tokyo, Japan.
Abstract
BACKGROUNDS: Acotiamide is a novel acetylcholinesterase inhibitor for treatment of postprandial distress syndrome (PDS) symptoms of functional dyspepsia (FD). This European phase 3 open-label safety trial has been conducted to evaluate the long-term safety of acotiamide and explore the efficacy of acotiamide on PDS symptoms using the validated LPDS, quality of life using SF-36 and SF-NDI, and work productivity using WPAI. METHODS: FD-PDS patients (defined by ROME III criteria) aged ≥18 years with active PDS symptoms and without predominant overlapping symptoms of epigastric pain syndrome and related disorders were enrolled to receive 100 mg acotiamide three times daily for 1 year. Patients' safety profile and efficacy of acotiamide were monitored. KEY RESULTS: The majority of patients (81.6%) maintained exposure to acotiamide for >50 weeks, with a mean duration of 320.3 days. No specific clinically significant safety concerns have been shown, with no deaths, treatment-related severe/serious adverse events, or any clinically significant laboratory test results. Although being an open-label trial, acotiamide showed a change in severity larger than the minimum clinically important difference at weeks 1 and 2 for postprandial fullness and early satiation (meal-related symptoms), and showed improvement of quality of life and work productivity from the first measurement (at week 12) up to 1 year. CONCLUSIONS & INFERENCES: The long-term safety of acotiamide treatment was confirmed. A clinically important change for PDS symptoms, QoL, and work productivity was suggested; however a controlled trial is required to confirm this hypothetic efficacy of acotiamide. (NCT01973790).
BACKGROUNDS: Acotiamide is a novel acetylcholinesterase inhibitor for treatment of postprandial distress syndrome (PDS) symptoms of functional dyspepsia (FD). This European phase 3 open-label safety trial has been conducted to evaluate the long-term safety of acotiamide and explore the efficacy of acotiamide on PDS symptoms using the validated LPDS, quality of life using SF-36 and SF-NDI, and work productivity using WPAI. METHODS:FD-PDSpatients (defined by ROME III criteria) aged ≥18 years with active PDS symptoms and without predominant overlapping symptoms of epigastric pain syndrome and related disorders were enrolled to receive 100 mg acotiamide three times daily for 1 year. Patients' safety profile and efficacy of acotiamide were monitored. KEY RESULTS: The majority of patients (81.6%) maintained exposure to acotiamide for >50 weeks, with a mean duration of 320.3 days. No specific clinically significant safety concerns have been shown, with no deaths, treatment-related severe/serious adverse events, or any clinically significant laboratory test results. Although being an open-label trial, acotiamide showed a change in severity larger than the minimum clinically important difference at weeks 1 and 2 for postprandial fullness and early satiation (meal-related symptoms), and showed improvement of quality of life and work productivity from the first measurement (at week 12) up to 1 year. CONCLUSIONS & INFERENCES: The long-term safety of acotiamide treatment was confirmed. A clinically important change for PDS symptoms, QoL, and work productivity was suggested; however a controlled trial is required to confirm this hypothetic efficacy of acotiamide. (NCT01973790).
Authors: Michael Camilleri; Victor Chedid; Alexander C Ford; Ken Haruma; Michael Horowitz; Karen L Jones; Phillip A Low; Seon-Young Park; Henry P Parkman; Vincenzo Stanghellini Journal: Nat Rev Dis Primers Date: 2018-11-01 Impact factor: 52.329